Considerations for Initial Therapy in Acute Heart Failure

Considerationsfor Initial Therapy in Acute Heart Failure

Considerationsfor initial therapy in acute heart failure

Thearticle points out that the acute heart failure treatment relies onthe proper diagnosis of problems that may be associated with thecondition. Thereby, health care professionals can put in more effortto ensure they can come up with strategies that will reduce theseverity and effects of acute heart failure (Peacock, Chad, Cannon,Singer, and Hiestand, 2015). One of the aspects that healthprofessionals may put in place is the use of proper drugs that areeffective on patients, thereby, reducing the detrimental effectsassociated with heart failure.

Thearticle further outlines that acute heart failure causes high ratesof mortality and morbidity among patients that are typically taken tothe emergency department. Also, the case points out the need to comeup with better processes that may reduce the effects brought about byexposure to given health problems. It is also important to note thatthe various therapies that are usually put in place to lessen theseverity of the health issue may change from time to time. Notably,the activity is carried out with a view of making use of drugs thathave high potency and bear the likelihood of bringing about thedesired outcomes in heart failure management in the long run.

Additionally,the article explains the different drugs that have been quitepertinent in reducing the extent of harm caused by heart failure.These are, generally, medications that help to stimulate the work ofheart muscles and, therefore, enable them to work to their maximumcapacity (Lavie, Ventura, Milani, &amp Arena, 2015). Besides, theyhelp in enhancing the interaction of the heart with other organs insuch a way that there may be a proper flow of blood and, in a waythat does not compromise its efficient working. Some of the drugs,especially those associated with vasoactive therapy include dopamine,nitroglycerin, dobutamine, and nesirine. Some of the new treatmentsthat are proposed and appear to present high levels of potency areserelaxin. Particularly, this drug is highly effective, because itinduces vasodilation, thereby improving the capability of the heartto pump blood to other parts of the body and enhance its overallcapacity. Notably, it was tested in two trials. The first testinvolved 180 days with a group of people being administered with thereal drug while 67 others were being administered with placebos. Onthe other hand, the second trial involved providing some patientswith acute heart failure with serelaxin while providing 68 otherswith a placebo. In the end, researchers proved that the drug waseffective in reducing of acute heart failure cases.

Notably,the drugs help to improve the heart’s response, especially amongpatients who are regularly hospitalized with various heart problems.In such situations, they contribute to the improvement of the generalquality of life of patients. Also, the article points out thatpatients suffering from acute heart failure should quickly seekmedical action. Consequently, this will increase the likelihood ofthe drug subduing the adverse effects of the condition (Gold, VanVeldhuisen, Hauptman, Borggrefe, Kubo, Lieberman, &amp Schwartz,2016). They also reduce the amount of time that may be used toadvance a given therapy and, therefore, subdue the suffering thatpatients could go through as they follow through a given prescriptiontill the end. Remarkably, the hastening of treatment reduces cases ofmortality that could result from acute heart failure conditions,especially when the said condition is progressing quite fast.

Inspite of the treatment that may be leveled towards acute failure,several challenges lie in this aspect of diagnosis and administeringdrug regimen. One of them lies in the operations at health facilitieswhich could be highly procedural, thereby reducing the time which agiven individual could be administered with the required treatment(Pfeffer, Claggett, Assmann, Boineau, Anand, Clausell, &amp Heitner,2015). Particularly, where the time taken to administer treatment isquite long, some patients could suffer in immense ways that result indeaths. Another issue also lies in the general inability of patientsto respond quickly to cases of acute heart failure. Notably, thissituation could be as a result of the inability of individuals to gothrough a medical examination to identify any significant symptoms.As a result, they could fail to take proper precautionary measuressuch as being put on a medical therapy that could reduce any case ofheart failure or general heart problems.

Inconclusion, the article points out to the extent which prescriptivepharmaceutical therapy has contributed towards ensuring that peoplesuffering from heart failure can attain good health. Also, it notesthat constant studies continue to be conducted in the area, outliningproblems associated with current therapy as well as coming up withways through which current gaps may be filled. Consequently, this isbound to address the issue of heart failure with high levels ofsuccess in the end.


Gold,M. R., Van Veldhuisen, D. J., Hauptman, P. J., Borggrefe, M., Kubo,S. H., Lieberman, R. A., … &amp Schwartz, P. J. (2016). VagusNerve Stimulation for the Treatment of Heart Failure: The INOVATE-HFTrial.&nbspJournalof the American College of Cardiology.

Lavie,C. J., Ventura, H. O., Milani, R. V., &amp Arena, R. (2015).Critical impact of fitness in the prevention and treatment of heartfailure.&nbspAmericanheart journal,&nbsp169(2),194-196.

Peacock,W.F., Chad M. Cannon, C.M., Singer, A.J &amp Hiestand. B, C.(2015). Considerations for initial therapy in the treatment of acuteheart failure

Pfeffer,M. A., Claggett, B., Assmann, S. F., Boineau, R., Anand, I. S.,Clausell, N., … &amp Heitner, J. F. (2015). Regional variation inpatients and outcomes in the Treatment of Preserved Cardiac FunctionHeart Failure With an Aldosterone Antagonist (TOPCAT)trial.&nbspCirculation,&nbsp131(1),34-42.